• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    9/13/23 1:31:12 PM ET
    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $AVTX alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) stock moved upwards by 54.3% to $0.19 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 254.7 million shares, making up 2392.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.8 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) stock rose 51.99% to $0.84. Trading volume for this security as of 13:30 EST is 32.3 million, which is 3640.6% of its average full-day volume over the last 100 days. The company's market cap stands at $19.9 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares moved upwards by 40.46% to $0.18. Trading volume for this security as of 13:30 EST is 105.9 million, which is 4299.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.5 million.
    • Rocket Pharmaceuticals (NASDAQ:RCKT) stock rose 36.88% to $20.93. Trading volume for Rocket Pharmaceuticals's stock is 18.9 million as of 13:30 EST. This is 3117.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 billion.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 32.16% to $0.51. As of 13:30 EST, this security is trading at a volume of 104.6 million shares, making up 269.5% of its average full-day volume over the last 100 days. The company's market cap stands at $81.1 million.
    • Nemaura Medical (NASDAQ:NMRD) shares increased by 27.14% to $0.45. The current volume of 2.3 million shares is 1585.8% of Nemaura Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $12.8 million.

    Losers

    • Eiger BioPharmaceuticals (NASDAQ:EIGR) shares fell 44.6% to $0.38 during Wednesday's regular session. Trading volume for Eiger BioPharmaceuticals's stock is 2.2 million as of 13:30 EST. This is 502.6% of its average full-day volume over the last 100 days. The company's market cap stands at $16.9 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares fell 37.16% to $0.01. Trading volume for this security as of 13:30 EST is 1.6 million, which is 335.8% of its average full-day volume over the last 100 days.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock fell 23.73% to $4.5. The market value of their outstanding shares is at $66.3 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock decreased by 17.56% to $0.07. Infinity Pharmaceuticals's stock is trading at a volume of 4.9 million shares as of 13:30 EST. This is 142.2% of its average full-day volume over the last 100 days. The company's market cap stands at $6.3 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock decreased by 16.4% to $5.15. As of 13:30 EST, Creative Medical Tech's stock is trading at a volume of 784.1K, which is 1027.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.3 million.
    • cbdMD (AMEX:YCBD) stock decreased by 14.29% to $1.2. cbdMD's stock is trading at a volume of 133.5K shares as of 13:30 EST. This is 269.1% of its average full-day volume over the last 100 days. The company's market cap stands at $3.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $CELZ
    $EIGR
    $IMPL

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Rocket Pharmaceuticals Inc.
    $RCKT
    11/18/2025Neutral → Underweight
    Analyst
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Rocket Pharmaceuticals Inc.
    $RCKT
    8/20/2025$10.00Neutral → Buy
    BofA Securities
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Rocket Pharmaceuticals Inc.
    $RCKT
    7/25/2025$4.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bjork Elisabeth bought $34,400 worth of shares (10,000 units at $3.44), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    1/6/26 4:05:11 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bjork Elisabeth bought $34,100 worth of shares (10,000 units at $3.41), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/27/25 8:54:13 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Shah Gaurav bought $101,600 worth of shares (20,000 units at $5.08), increasing direct ownership by 3% to 792,680 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    4/14/25 6:57:31 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by Analyst

    Analyst downgraded Rocket Pharmaceuticals from Neutral to Underweight

    11/18/25 9:30:30 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sullivan Christopher Ryan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:14:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:13:22 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aminov Erez

    4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    4/1/26 5:00:00 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    SEC Filings

    View All

    SEC Form SC TO-C filed by Rocket Pharmaceuticals Inc.

    SC TO-C - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    4/3/26 8:30:23 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Avalo Therapeutics Inc.

    144 - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 4:48:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - cbdMD, Inc. (0001644903) (Filer)

    4/1/26 4:05:49 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

    Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care modelsCHARLOTTE, N.C., April 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.

    4/1/26 8:30:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

    ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress

    3/31/26 5:05:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric Disease Priority Review Voucher Company to host conference call today, March 27 at 8:30 AM ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnet

    3/27/26 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

    6/18/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Financials

    Live finance-specific insights

    View All

    ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

    ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress

    3/31/26 5:05:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric Disease Priority Review Voucher Company to host conference call today, March 27 at 8:30 AM ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnet

    3/27/26 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AVTX
    $CELZ
    $EIGR
    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care